Expert OCD Therapy in Newcastle West, Limerick, Cork, Dungarvan & Online – Helping Clients Across Ireland, the UK & Worldwide

Are you struggling with obsessive thoughts, compulsive behaviours, or overwhelming anxiety? Obsessive-Compulsive Disorder (OCD) can take over your life, making even simple daily tasks feel impossible. At Claire Russell Therapy, we specialise in providing professional OCD counselling and psychotherapy to help you break free from the cycle of intrusive thoughts and compulsions.

Our evidence-based OCD treatment services are available in Newcastle West, Limerick, Cork, Dungarvan, and online, so you can access expert support no matter where you are in Ireland, the UK, or worldwide. If you are looking for an experienced OCD specialist, you’ve come to the right place.

Understanding OCD: What You Need to Know

OCD is a serious but treatable condition characterised by persistent, generally negative, unwanted thoughts (obsessions) and repetitive behaviours or mental rituals or systems (compulsions). These symptoms can be time-consuming and distressing, significantly interfering with your daily life, relationships, and emotional well-being.

Common Obsessions in OCD:

  • Fear of contamination (germs, illness, toxins ).
  • Intrusive thoughts of harm, aggression, or violence.
  • Unwanted blasphemous or sexual thoughts.
  • Excessive worries about symmetry, order, or perfection.
  • Irrational fears about responsibility, morality, or making mistakes.

Common Compulsions in OCD:

  • Excessive handwashing, cleaning, or sanitising with or without a specific order or systematic way.
  • Repeated checking things (doors, locks, appliances, personal safety).
  • Counting, tapping, or repeating words silently to “neutralise” thoughts.
  • Organising and arranging objects in a specific order.
  • Seeking constant reassurance from loved ones or professionals.

OCD is not just about being overly tidy or particular—it is a debilitating condition that can create significant worry, upset and distress. Fortunately, with the right OCD therapy, recovery is possible.

The Best OCD Treatment: Evidence-Based Therapies That Work

At Claire Russell Therapy, we use scientifically proven treatments that help clients successfully manage and reduce OCD symptoms. We offer therapy sessions in-person in Newcastle West, Limerick, Cork, and Dungarvan, as well as online for clients across Ireland, the UK, and globally.

Cognitive-Behavioural Therapy (CBT) & Exposure and Response Prevention (ERP)

CBT is the most effective treatment for OCD, and Exposure and Response Prevention (ERP) therapy is considered the gold standard. ERP helps you gradually face your fears while resisting compulsions, breaking the obsessive-compulsive cycle over time (Foa et al., 2005). Our specialist OCD therapy in Limerick, Cork, Dungarvan, and online ensures you receive personalised, expert treatment tailored to your specific needs.

Mindfulness-Based Therapy & Acceptance and Commitment Therapy (ACT)

In addition to CBT and ERP, many clients benefit from mindfulness and acceptance-based approaches, such as Mindfulness-Based Cognitive Therapy (MBCT) and Acceptance and Commitment Therapy (ACT). These therapies teach you how to accept uncertainty and reduce avoidance behaviours, helping you manage intrusive thoughts more effectively (Twohig et al., 2010).

Hypno-Psychotherapy for OCD: A Holistic Approach

For clients who seek a more holistic and subconscious approach to overcoming OCD, Hypno-Psychotherapy can be a powerful tool. This therapy integrates clinical medical hypnotherapy, clinical hypnotherapy,  hypnosis with psychotherapeutic techniques, allowing you to access and reframe deep-rooted thought patterns that fuel obsessive-compulsive behaviours. Hypno-Psychotherapy can help:

  • Reduce anxiety and stress related to obsessive thoughts.
  • Rewire negative subconscious beliefs.
  • Strengthen your ability to resist compulsive urges.
  • Enhance relaxation and emotional resilience.

Hypno-Psychotherapy is available in Newcastle West, Limerick, Cork, Dungarvan, and online, making it a flexible and accessible option for clients via zoom, or remotely ONLINE across Ireland, the UK, and worldwide.

Online OCD Therapy: Get Help from Anywhere in the World

Can’t attend in person? No problem! We offer proven experienced online OCD therapy to clients across Ireland, the UK, and worldwide. Whether you’re based in anywhere in Ireland, the UK,  Newcastle West, Limerick, Cork, Dungarvan, Australia, New Zealand, London, Dublin, or anywhere else in the world, you can receive expert therapy from the comfort of your own home. Online therapy is just as effective as in-person sessions, providing flexible, accessible support no matter your location.

Why Choose Claire Russell Therapy for OCD Treatment?

Finding the right OCD therapist is crucial for successful treatment. Here’s why so many clients trust Claire Russell Therapy:

✔ Specialist in OCD Therapy: Years of experience helping clients overcome OCD, anxiety, and related disorders.

✔ Evidence-Based Approaches: We use clinically proven treatments like CBT, ERP, MBCT, ACT, and Hypno-Psychotherapy.

✔ Flexible Online & In-Person Sessions: Get therapy in Newcastle West, Limerick, Cork, Dungarvan, or online anywhere in Ireland, the UK, USA, Australia and worldwide.

✔ Compassionate & Confidential Support: We provide a safe, non-judgmental space where you can discuss your concerns openly.

✔ Worldwide Access: No matter where you are, our online therapy options ensure you receive top-quality care.

If you’re looking for the best OCD therapy in Limerick, Cork, Dungarvan, Newcastle West, or online, we’re here to help.

Take the First Step Towards OCD Recovery Today

OCD is highly treatable, and you don’t have to struggle alone. Seeking professional help is the first step toward regaining control over your life. Whether you need ERP therapy, CBT for OCD, Hypno-Psychotherapy, online OCD counselling, or specialist support in Newcastle West, Limerick, Youghal, Cork, Dungarvan, Waterford we are here for you.

Book Your Consultation Now

Don’t let OCD hold you back any longer. Contact Claire Russell Therapy today to schedule your first session and start your journey toward freedom from OCD.

☎ Call or email us to arrange your initial consultation.

Offering therapy in Newcastle West, Limerick, Cork, Dungarvan, and online across Ireland, the UK, and worldwide.

Academic References

  • Foa, E. B., et al. (2005). Randomized trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. American Journal of Psychiatry, 162(1), 151-161.
  • Pauls, D. L., et al. (2014). The inheritance of obsessive-compulsive disorder. American Journal of Medical Genetics, 127(1), 35-40.
  • Stein, D. J., et al. (2019). Obsessive-compulsive disorder and the brain: A review. Molecular Psychiatry, 24(12), 1659-1675.
  • Swedo, S. E., et al. (2012). Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS). Journal of Child and Adolescent Psychopharmacology, 22(4), 267-271.
  • Twohig, M. P., et al. (2010). Acceptance and commitment therapy for obsessive-compulsive disorder: A pilot study. Behavior Modification, 34(2), 175-193.
  • AACP. Practice parameters for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. AACAP. Journal of the American Academy of Child and Adolescent Psychiatry. 1998;37(Suppl 10):27S–45S. [PubMed]
  • Abram KM, Teplin LA, McClelland GM, et al. Comorbid psychiatric disorders in youth in juvenile detention. Arch Gen Psychiatry. 2003;60:1097–1108. [PMC free article] [PubMed]
  • Abramowitz JS. Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. Journal of Consulting and Clinical Psychology. 1997;65:44–52. [PubMed]
  • Abramowitz JS. Treatment of obsessive-compulsive disorder in patients who have comorbid major depression. Journal of Clinical Psychology. 2004;60:1133–1141. [PubMed]
  • Abramowitz JS, Schwartz SA, Moore KM, et al. Obsessive-compulsive symptoms in pregnancy and the puerperium: a review of the literature. Journal of Anxiety Disorders. 2003;17:461–478. [PubMed]
  • Ackerman DL, Greenland S. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. Journal of Clinical Psychopharmacology. 2002;22:309–317. [PubMed]
  • Albano AM, DiBartolo PM. Cognitive-behavioral treatment of obsessive-compulsive disorder and social phobia in children and adolescents, Innovations in Clinical Practice. Vande Creek L, editor. Vol. 15. Sarasota, Florida: Professional Resource Exchange Inc.; 1997. pp. 41–58.
  • Albert U, Aguglia E, Maina G, et al. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. Journal of Clinical Psychiatry. 2002;63:1004–1009. [PubMed]
  • Albert U, Maina G, Forner F, et al. DSM-IV obsessive-compulsive personality disorder: Prevalence in patients with anxiety disorders and in healthy comparison subjects. Comprehensive Psychiatry. 2004;45:325–332. [PubMed]
  • Albertini RS, Phillips KA. Thirty-three cases of body dysmorphic disorder in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry. 1999;38:453–459. [PubMed]
  • Alonso P, Pujol J, Cardoner N, et al. Right prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: a double-blind, placebo-controlled study. American Journal of Psychiatry. 2001;158:1143–1145. [PubMed]
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. Washington, DC: APA; 1980. DSM-III.
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: APA; 1994. DSM-IV.
  • Amin MM, Ban TA, Pecknold JC, et al. Clomipramine (Anafranil) and behaviour therapy in obsessive-compulsive and phobic disorders. Journal of International Medical Research. 1977;5:33–37. [PubMed]
  • Amir N, Freshman M, Foa EB. Family distress and involvement in relatives of obsessive-compulsive disorder patients. Journal of Anxiety Disorders. 2000;14:209–217. [PubMed]
  • Ananth J, Pecknold JC, van den Steen N, et al. Double-blind comparative study of clomipramine and amitriptyline in obsessive neurosis. Progress in Neuro-Psychopharmacology. 1981;5:257–262. [PubMed]
  • Anderson D, Ahmed A. Treatment of patients with intractable obsessive-compulsive disorder with anterior capsular stimulation: case report. Journal of Neurosurgery. 2003;98:1104–1108. [PubMed]
  • Ansseau M, Legros JJ, Mormont C, et al. Intranasal oxytocin in obsessive-compulsive disorder. Psychoneuroendocrinology. 1987;12:231–236. [PubMed]
  • Ansseau M, Bejerot S, Blauwblomme JF, et al. A double-blind study to compare the maintenance of efficacy and relapse rates in patients with obsessive-compulsive disorder who responded to paroxetine, clomipramine or placebo in the short-term study 136. [April 2004]. http://ctr​.gsk.co.uk​/Summary/paroxetine/studylist.asp [Study No.: MY-1056/BRL-029060/1/CPMS-241 (PAR 241)]
  • Antonelli F, de Gregorio M, Dionisio A. Trazodone in the treatment of psychoneuroses: a double-blind study. Current Therapeutic Research, Clinical and Experimental. 1973;15:799–804. [PubMed]
  • Antony MM, Roth D, Swinson RP, et al. Illness intrusiveness in individuals with panic disorder, obsessive-compulsive disorder, or social phobia. Journal of Nervous and Mental Disease. 1998;186:311–315. [PubMed]
  • Aouizerate B, Pujol H, Grabot D, et al. Body dysmorphic disorder in a sample of cosmetic surgery applicants. European Psychiatry. 2003;18:365–368. [PubMed]
  • Apter A, Bernhout E, Tyano S. Severe obsessive compulsive disorder in adolescence: a report of eight cases. Journal of Adolescence. 1984;7:349–358. [PubMed]
  • Apter A, Horesh N, Gothelf D, et al. Depression and suicidal behavior in adolescent inpatients with obsessive compulsive disorder. Journal of Affective Disorders. 2003;75:181–189. [PubMed]
  • Askin R, Turan M, Cilli AS, et al. Clomipramine versus sertraline in the treatment of obsessive compulsive disorder. Klinik Psikofarmakoloji Buelteni. 1999;9:133–138.
  • Atmaca M, Kuloglu M, Tezcan E, et al. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. International Clinical Psychopharmacology. 2002;17:115–119. [PubMed]
  • Baer L, Greist JH. An interactive computer-administered self-assessment and self-help program for behavior therapy. J Clin Psychiatry. 1997;58 Suppl 12:23–28. [PubMed]
  • Baer L, Rauch SL, Ballantine HT Jr, et al. Cingulotomy for intractable obsessive-compulsive disorder: Prospective long-term follow-up of 18 patients. Archives of General Psychiatry. 1995;52:384–392. [PubMed]
  • Bailer DC, Burnham D, Oakes R. Long-term treatment with paroxetine of outpatients with obsessive-compulsive disorder: an extension of the companion study. [April 2004]. http://ctr​.gsk.co.uk​/Summary/paroxetine/studylist.asp [Study No.: MY-1053/BRL-029060/CPMS-127]
  • Bakken K, Landheim AS, Vaglum P. Primary and secondary substance misusers: do they differ in substance-induced and substance-independent mental disorders? Alcohol and Alcoholism. 2003;38:54–59. [PubMed]
  • Barker AT, Jalinous R, Freeston IL. Non-invasive magnetic stimulation of human motor cortex. Lancet. 1985;1(8437):1106–1107. [PubMed]
  • Barr LC, Goodman WK, Anand A, et al. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. American Journal of Psychiatry. 1997;154:1293–1295. [PubMed]
  • Barrett P, Shortt A, Healy L. Do parent and child behaviours differentiate families whose children have obsessive-compulsive disorder from other clinic and non-clinic families? Journal of Child Psychology and Psychiatry. 2002;43:597–607. [PubMed]
  • Barrett P, Healy L, March JS. Behavioral avoidance test for childhood obsessive-compulsive disorder: a home-based observation. American Journal of Psychotherapy. 2003;57:80–100. [PubMed]
  • Barrett P, Healy-Farrell L, March JS. Cognitive-behavioral family treatment of childhood obsessive-compulsive disorder: a controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry. 2004;43:46–62. [PubMed]
  • Barth FD. Obsessional thinking as ‘paradoxical action’ Bulletin of the Menninger Clinic. 1990;54:499–511. [PubMed]
  • Bartlett JR, Bridges PK. The extended subcaudate tractotomy lesion, Neurosurgical Treatment in Psychiatry, Pain and Epilepsy. Sweet WH, Obrador S, Martin-Rodriguez JG, editors. Baltimore: University Park Press; 1977.
  • Beale MD, Kellner CH, Pritchett JT, et al. ECT for OCD. J Clin Psychiatry. 1995;56(2):81–82. [PubMed]
  • Beasley CM Jr, Potvin JH, Masica DN, et al. Fluoxetine: no association with suicidality in obsessive-compulsive disorder. Journal of Affective Disorders. 1992;24:1–10. [PubMed]
  • Becker D, North MM. The virtual reality therapy system: VRT-2002. Cyberpsychology and Behavior. 1998;1:401–403.
  • Bejerot S. Psychosurgery for obsessive-compulsive disorder: concerns remain. Acta Psychiatrica Scandinavica. 2003;107:241–243. [PubMed]
  • Bejerot S, Bodlund O. Response to high doses of citalopram in treatment-resistant obsessive-compulsive disorder. Acta Psychiatrica Scandinavica. 1998;98:423–424. [PubMed]
  • Benazon NR, Ager J, Rosenberg DR. Cognitive behavior therapy in treatment-naive children and adolescents with obsessive-compulsive disorder: an open trial. Behaviour Research and Therapy. 2002;40:529–539. [PubMed]
  • Bergeron R, Ravindran AV, Chaput Y, et al. Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study. Journal of Clinical Psychopharmacology. 2002;22:148–154. [PubMed]
  • Berle D, Starcevic V. Thought-action fusion: review of the literature and future directions. Clinical Psychology Review. 2005;25:263–284. [PubMed]
  • Berlin JA. Does blinding of readers affect the results of meta-analysis? University of Pennsylvania Meta-Analysis Blinding Study Group. Lancet. 2001;350(9072):185–186. [PubMed]
  • Biederman J, Petty C, Faraone SV, et al. Moderating effects of major depression on patterns of comorbidity in patients with panic disorder. Psychiatry Research. 2004;126:143–149. [PubMed]
  • Bisserbe JC, Lane RM, Flament MF. A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder. European Psychiatry. 1997;12:82–93. [PubMed]
  • Black A. The natural history of obsessional neurosis, Obsessional States. Beech HR, editor. London: Methuen; 1974. pp. 19–54.
  • Black D, Noyes R. Obsessive-compulsive disorder and axis II. International Review of Psychiatry. 1997;9:111–118.
  • Black DW, Gaffney G, Schlosser S, et al. The impact of obsessive-compulsive disorder on the family: preliminary findings. Journal of Nervous and Mental Disease. 1998;186:440–442. [PubMed]
  • Black DW, Gaffney GR, Schlosser S, et al. Children of parents with obsessive-compulsive disorder: a 2-year follow-up study. Acta Psychiatrica Scandinavica. 2003;107:305–313. [PubMed]
  • Blier P, Bergeron R. Sequential administration of augmentation strategies in treatment-resistant obsessive-compulsive disorder: preliminary findings. International Clinical Psychopharmacology. 1996;11:37–44. [PubMed]
  • Bloch S, Glue P. Psychotherapy and dysmorphophobia: a case report. British Journal of Psychiatry. 1988;152:271–274. [PubMed]
  • Bobes J, Gonzalez MP, Bascaran MT, et al. Quality of life and disability in patients with obsessive-compulsive disorder. European Psychiatry. 2001;16:239–245. [PubMed]
  • Boehm T. Sara in her fourth analytic year. International Journal of PsychoAnalysis. 2002;83:1003–1008. [PubMed]
  • Boersma K, Den Hengst S, Dekker J, et al. Exposure and response prevention in the natural environment: a comparison with obsessive-compulsive patients. Behaviour Research and Therapy. 1976;14:19–24. [PubMed]
  • Bogetto F, Bellino S, Vaschetto P, et al. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Research. 2000;96:91–98. [PubMed]
  • Bogetto F, Albert U, Maina G. Sertraline treatment of obsessive-compulsive disorder: efficacy and tolerability of a rapid titration regimen. European Neuropsychopharmacology. 2002;12:181–186. [PubMed]
  • Bohne A, Wilhelm S, Keuthen NJ. Prevalence of body dysmorphic disorder in a German college student sample. Psychiatry Research. 2002;109:101–104. [PubMed]
  • Bolton D, Turner T. Obsessive-compulsive neurosis with conduct disorder in adolescence: a report of two cases. Journal of Child Psychology and Psychiatry and Allied Disciplines. 1984;25:133–139. [PubMed]
  • Bolton D, Collins S, Steinberg D. The treatment of obsessive-compulsive disorder in adolescence: a report of fifteen cases. British Journal of Psychiatry. 1983;142:456–464. [PubMed]
  • Bolton D, Luckie M, Steinberg D. Obsessive-compulsive disorder treated in adolescence: 14 long-term case histories. Clinical Child Psychology and Psychiatry. 1996;1:409–430.
  • Bouvard M. A standardized cognitive-behavioural group treatment program for obsessive compulsive disorder: preliminary outcomes. Encephale. 2002;28:439–446. [PubMed]
  • Braddock LE. Dysmorphophobia in adolescence: a case report. British Journal of Psychiatry. 1982;140:199–201. [PubMed]
  • Brawman-Mintzer O, Lydiard RB, Phillips KA, et al. Body dysmorphic disorder in patients with anxiety disorders and major depression: a comorbidity study. American Journal of Psychiatry. 1995;152:1665–1667. [PubMed]
  • Brown KW, McGoldrick T, Buchanan R. Body dysmorphic disorder: seven cases treated with eye movement desensitization and reprocessing. Behavioural and Cognitive Psychotherapy. 1997;25:203–207.
  • Burgy M. The narcissistic function in obsessive-compulsive neurosis. American Journal of Psychotherapy. 2001;55:65–73. [PubMed]
  • Burnham DB, Apter J, Ballenger JC, et al. Paroxetine versus clomipramine and placebo in the treatment of obsessive-compulsive disorder. [April 2004]. http://ctr​.gsk.co.uk​/Summary/paroxetine/studylist.asp [Study No.: MY-1028/BRL-029060/1/CPMS-118]
  • Butters JW, Cash TF. Cognitive-behavioral treatment of women’s body-image dissatisfaction. Journal of Consulting and Clinical Psychology. 1987;55:889–897. [PubMed]
  • Byerly MJ, Goodman WK, Christensen R. High doses of sertraline for treatment-resistant obsessive-compulsive disorder. American Journal of Psychiatry. 1996;153:1232–1233. [PubMed]
  • Calvocoressi L, Lewis B, Harris M, et al. Family accommodation in obsessive-compulsive disorder. American Journal of Psychiatry. 1995;152:441–443. [PubMed]
  • Calvocoressi L, Mazure CM, Kasl SV, et al. Family accommodation of obsessive-compulsive symptoms: instrument development and assessment of family behavior. Journal of Nervous and Mental Disease. 1999;187:636–642. [PubMed]
  • Campisi TA. PhD thesis. Hofstra University; Hempstead, New York: 1995. Exposure plus response prevention in the treatment of body dysmorphic disorder.
  • Carpenter DJ, Schaefer DM, Lawnnson S, et al. A 38-week, two phase, multicentre study to investigate the safety and effectiveness of paroxetine (10–60) mg/day) in the treatment of children and adolescent outpatients with obsessive-compulsive disorder. [April 2004]. http://ctr​.gsk.co.uk​/Summary/paroxetine/studylist.asp [Study No.: BRL-029060/RSD-100W81/1/CPMS-453]
  • Carroll BJ. Response of major depression with psychosis and body dysmorphic disorder to ECT. American Journal of Psychiatry. 1994;158:288–289. [PubMed]
  • Carter L. Body dysmorphia. In Electronic Response to Katharine A. Phillips & David J. Castle, Body dysmorphic disorder in men, BMJ. 2001. pp. 1015–1016. http://bmj​.bmjjournals​.com/cgi/eletters/323/7320/1015#17324 . [PMC free article] [PubMed]
  • Casas M, Alvarez E, Duro P, et al. Antiandrogenic treatment of obsessive-compulsive neurosis. Acta Psychiatrica Scandinavica. 1986;73:221–222. [PubMed]
  • Casey DA, Davis MH. Obsessive-compulsive disorder responsive to electroconvulsive therapy in an elderly woman. South African Medical Journal. 1994;87:862–864. [PubMed]
  • Cassano GB, Castrogiovanni P, Mauri M. A multicenter controlled trial in phobic-obsessive psychoneurosis: the effect of chlorimipramine and of its combinations with haloperidol and diazepam. Progress in Neuro-Psychopharmacology. 1981;5:129–138. [PubMed]
  • Castle DJ, Molton M, Hoffman K, et al. Correlates of dysmorphic concern in people seeking cosmetic enhancement. Australian and New Zealand Journal of Psychiatry. 2004;38:439–444. [PMC free article] [PubMed]
  • Cela JA. A classical case of a severe obsessive compulsive defense. Modern Psychoanalysis. 1995;20:271–277.
  • Chakrabarti S, Kulhara P, Verma SK. The pattern of burden in families of neurotic patients. Social Psychiatry and Psychiatric Epidemiology. 1993;28:172–177. [PubMed]
  • Chambless DL, Steketee G. Expressed emotion and behavior therapy outcome: a prospective study with obsessive-compulsive and agoraphobic outpatients. Journal of Consulting and Clinical Psychology. 1999;67:658–665. [PubMed]
  • Chambless DL, Bryan AD, Aiken LS, et al. Predicting expressed emotion: a study with families of obsessive-compulsive and agoraphobic outpatients. Journal of Family Psychology. 2001;15:225–240. [PubMed]
  • Chatterji NN. Psychoanalysis of an artist with obsessional symptoms. Samiksa. 1963;17:173–197.
  • Chiocca EA, Matuza RL. Neurosurgical therapy of obsessive compulsive disorder, Obsessive-Compulsive Disorders: Theory and Management. Jenike MA, Baer L, Minichiello WE, editors. Chicago: Year Book Medical; 1990. pp. 283–294.
  • Chouinard G. Sertraline in the treatment of obsessive compulsive disorder: two double-blind, placebo-controlled studies. Int Clin Psychopharmacol. 1992 Oct;7 Suppl 2:37–41. [PubMed]
  • Chouinard G, Goodman W, Greist J, et al. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacology Bulletin. 1990;26:279–284. [PubMed]
  • Chowdhury U, Frampton I, Heyman I. Clinical characteristics of young people referred to an obsessive compulsive disorder clinic in the United Kingdom. Clinical Child Psychology and Psychiatry. 2004;9:395–401.
  • Christensen H, Hadzi-Pavlovic D, Andrews G, et al. Behavior therapy and tricyclic medication in the treatment of obsessive-compulsive disorder: a quantitative review. Journal of Consulting and Clinical Psychology. 1987;55:701–711. [PubMed]
  • Christensen DD, Laitinen LV, Schmidt LJ, et al. Anterior capsulotomy for treatment of refractory obsessive-compulsive disorder: results in a young and an old patient. Stereotactic and Functional Neurosurgery. 2002;79:234–244. [PubMed]
  • Chung MS, Huang SC, Tsai SJ, et al. Mania associated with electroconvulsive therapy in a patient with obsessive compulsive disorder. International Medical Journal. 2001;8:185–186.
  • Churchill JE. Hypnotherapy and conjoint family therapy: a viable treatment combination. American Journal of Clinical Hypnosis. 1986;28:170–176. [PubMed]
  • Clark DA. Cognitive-Behavioral Therapy for OCD. New York, NY: Guilford Press; 2004.
  • Clark DA, Beck AT. Clark-Beck Obsessive Compulsive Inventory. San Antonio, TX: The Psychological Corporation; 2002.
  • Clark DA, Sugrim I, Bolton D. Primary obsessional slowness: a nursing treatment programme with a 13-year-old male adolescent. Behaviour Research and Therapy. 1982;20:289–292. [PubMed]
  • Clarke DJ, Boer H, Whittington J, et al. Prader-Willi syndrome, compulsive and ritualistic behaviours: the first population-based survey. British Journal of Psychiatry. 2002;180:358–362. [PubMed]
  • Clomipramine Collaborative Study Group (CCSG). Clomipramine in the treatment of patients with obsessive-compulsive disorder. Archives of General Psychiatry. 1991;48:730–738. [PubMed]
  • Cochrane Collaboration. Review Manager (Rev Man) [427 for Windows]. Oxford, England: The Cochrane Collaboration; 2004.
  • Cordioli AV, Heldt E, Bochi DB, et al. Cognitive-behavioral group therapy in obsessive-compulsive disorder: a randomized clinical trial. Psychotherapy and Psychosomatics. 2003;72:211–216. [PubMed]
  • Coryell WH, Black DW, Kelly MW, et al. HPA axis disturbance in obsessive-compulsive disorder. Psychiatry Research. 1989;30:243–251. [PubMed]
  • Cosyns P, Caemaert J, Haaijman W, et al. Functional stereotactic neurosurgery for psychiatric disorders: an experience in Belgium and The Netherlands. Advances and Technical Standards in Neurosurgery. 1994;21:239–279. [PubMed]
  • Cottraux J, Mollard E, Bouvard M, et al. A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder. International Clinical Psychopharmacology. 1990;5:17–30. [PubMed]
  • Cottraux J, Messy P, Marks IM, et al. Predictive factors in the treatment of obsessive-compulsive disorders with fluvoxamine and/or behaviour therapy. Behavioural Psychotherapy. 1993;21:45–50.
  • Cottraux J, Note I, Yao SN, et al. A randomized controlled trial of cognitive therapy versus intensive behavior therapy in obsessive compulsive disorder. Psychotherapy and Psychosomatics. 2001;70:288–297. [PubMed]
  • Cox BJ, Swinson RP, Morrison B, et al. Clomipramine, fluoxetine, and behavior therapy in the treatment of obsessive-compulsive disorder: a meta-analysis. Journal of Behavior Therapy and Experimental Psychiatry. 1993;24:149–153. [PubMed]
  • Crago H. The anxious boys’ newsletter. Australian and New Zealand Journal of Family Therapy. 1995;16:29–37.
  • Crocq MA. Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment. European Psychiatry. 2002;17:296–297. [PubMed]
  • Cromarty P, Marks I. Does rational role-play enhance the outcome of exposure therapy in dysmorphophobia? A case study. British Journal of Psychiatry. 1995;167:399–402. [PubMed]
  • Cui YH. A double-blind trial of chlorimipramine and doxepin in obsessive-compulsive neurosis. Chung-Hua Shen Ching Ching Shen Ko Tsa Chih. [Chinese Journal of Neurology and Psychiatry]. 1986;19:279–281. Chinese. [PubMed]
  • Cumming S, Hay P, Lee T, et al. Neuropsychological outcome from psychosurgery for obsessive-compulsive disorder. Australian and New Zealand Journal of Psychiatry. 1995;29:293–298. [PubMed]
  • Dale RC, Heyman I. Post-streptococcal autoimmune psychiatric and movement disorders in children. British Journal of Psychiatry. 2002;181:188–190. [PubMed]
  • Dalton P. Family treatment of an obsessive-compulsive child: a case report. Family Process. 1983;22:99–108. [PubMed]
  • D’Amico G, Cedro C, Muscatello MR, et al. Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2003;27:619–623. [PubMed]
  • Dannon PN, Sasson Y, Hirschmann S, et al. Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial. European Neuropsychopharmacology. 2000;10:165–169. [PubMed]
  • De Araujo LA, Ito LM, Marks IM, et al. Does imagined exposure to the consequences of not ritualising enhance live exposure for OCD? A controlled study. I. Main outcome. British Journal of Psychiatry. 1995;167:65–70. [PubMed]
  • De Araujo LA, Ito LM, Marks IM. Early compliance and other factors predicting outcome of exposure for obsessive-compulsive disorder. British Journal of Psychiatry. 1996;169:747–752. [PubMed]
  • De Haan E, Hoogduin KA, Buitelaar JK, et al. Behavior therapy versus clomipramine for the treatment of obsessive-compulsive disorder in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry. 1998;37:1022–1029. [PubMed]
  • Den Boer JA, Westenberg HG. Oxytocin in obsessive compulsive disorder. Peptides. 1992;13:1083–1085. [PubMed]
  • Den Boer JA, Westenberg HG, Kamerbeek WD, et al. Effect of serotonin uptake inhibitors in anxiety disorders: a double-blind comparison of clomipramine and fluvoxamine. International Clinical Psychopharmacology. 1987;2:21–32. [PubMed]
  • Denys D, van der Wee N, van Megen HJ, et al. Double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. International Journal of Neuropsychopharmacology. 2002;5:S131–S132. [PubMed]
  • Denys D, van Megen H, Westenberg H. Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study. Journal of Clinical Psychiatry. 2002;63(8):700–703. [PubMed]
  • Denys D, van Megen H, Westenberg H. The adequacy of pharmacotherapy in outpatients with obsessive-compulsive disorder. International Clinical Psychopharmacology. 2002;17:109–114. [PubMed]
  • Denys D, van der Wee N, van Megen H, et al. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. Journal of Clinical Psychopharmacology. 2003;23:568–575. [PubMed]
  • Denys D, de Geus F, van Megen H, et al. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. Journal of Clinical Psychiatry. 2004;65:1040–1048. [PubMed]
  • Department of Health. Mental Health NSF (and the NHS Plan) Workforce Planning, Education and Training-Underpinning Programme: Adult Mental Health Services – Final Report by the Workforce Action Team. London: Department of Health; 2001.
  • Department of Health. Organising and Delivering Psychological Therapies. London: Department of Health; 2004.
  • Deri S. Case presentation. Psychoanalytic Review. 1990;77:535–554. [PubMed]
  • DerSimonian R, Laird N. Meta-analysis in Clinical Trials. Controlled Clinical Trials. 1986;7:177–188. [PubMed]
  • Desmarais PA, Lavallee YJ. Severe obsessive-compulsive syndrome in a 10 year old: a 3 year follow-up. Canadian Journal of Psychiatry – Revue Canadienne de Psychiatrie. 1988;33:405–408. [PubMed]
  • Detweiler MF, Albano AM. Covert symptoms of obsessive-compulsive disorder in children: a case study. Journal of Cognitive Psychotherapy. 2001;15:75–86.
  • DeVeaugh-Geiss J, Landau P, Katz R. Treatment of obsessive compulsive disorder with clomipramine. Psychiatric Annals. 1989;19:97–101.
  • DeVeaugh-Geiss J, Katz R, Landau P, et al. Clinical predictors of treatment response in obsessive compulsive disorder: exploratory analyses from multicenter trials of clomipramine. Psychopharmacology Bulletin. 1990;26:54–59. [PubMed]
  • DeVeaugh-Geiss J, Katz R, Landau P, et al. Clomipramine hydrochloride (Anafranil) in the treatment of obsessive-compulsive disorder: results from three multicentre trials, Understanding Obsessive-Compulsive Disorder (OCD). Jenike MA, Asberg M, editors. Toronto: Hogrefe and Huber Publishers; Bern: Hans Huber; 1991. pp. 46–51.
  • DeVeaugh-Geiss J, Moroz G, Biederman J, et al. Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder: a multicenter trial. Journal of the American Academy of Child and Adolescent Psychiatry. 1992;31:45–49. [PubMed]
  • De Waal MWM, Arnold IA, Eekhof JAH, et al. Prevalence, functional impairment and comorbidity with anxiety and depressive disorders. British Journal of Psychiatry. 2004;184:479–476. [PubMed]
  • Diamond BI, Borison RL, Katz R, et al. Rebound withdrawal reactions due to clomipramine. Psychopharmacology Bulletin. 1989;25:209–212. [PubMed]
  • Di Blasi Z, Harkness E, Ernst E, et al. Influence of context effects on health outcomes: a systematic review. Lancet. 2001;357(9258):757–762. [PubMed]
  • Doherr L, Reynolds S, Wetherly J, et al. Young children’s ability to engage in cognitive therapy tasks: associations with age and educational experience. Behavioural and Cognitive Psychotherapy. 2005;33:201–215.
  • Dormaar JMM. February man revisited. American Journal of Clinical Hypnosis. 1987;30:28–35. [PubMed]
  • Do Rosario-Campos MC, Leckman JF, Curi M, et al. A family study of early-onset obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet. 2005;136B(1):92–97. [PubMed]
  • Dougherty DD, Baer L, Cosgrove GR, et al. Prospective long-term follow-up of 44 patients who received cingulotomy for treatment-refractory obsessive-compulsive disorder. American Journal of Psychiatry. 2002;159:269–275. [PubMed]
  • Dreessen L, Hoekstra R, Arntz A. Personality disorders do not influence the results of cognitive and behavior therapy for obsessive compulsive disorder. Journal of Anxiety Disorders. 1997;11:503–521. [PubMed]
  • Drummond MF, O’Brien B, Stoddart GI, et al. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press; 1997.
  • Dubois AM. A double-blind study of two types of psychiatric treatments. Genitif. 1983;5:91–101. French.
  • Dufresne RG, Phillips KA, Vittorio CC, et al. A screening questionnaire for body dysmorphic disorder in a cosmetic dermatologic surgery practice. Dermatologic Surgery. 2001;27:457–462. [PubMed]
  • DuPont RL, Rice DP, Shiraki S, et al. Economic costs of obsessive compulsive disorder. Medical Interface. 1995;8:102–109. [PubMed]
  • Eccles M, Mason J. How to develop cost-conscious guidelines. Health Technology Assessment. 2001;5:1–69. [PubMed]
  • Eccles M, Freemantle N, Mason J. North of England evidence-based guideline development project: methods of developing guidelines for efficient drug use in primary care. BMJ. 1998;316:1232–1235. [PMC free article] [PubMed]
  • Eddy MF, Walbroehl GS. Recognition and treatment of obsessive-compulsive disorder. American Family Physician. 1998;57:1623–1624. [PubMed]
  • Einat H, Shaldubina A, Belmaker RH. Epi-inositol: a potential antidepressant. Drug Development Research. 2000;50:309–315.
  • El-Khatib HE, Dickey TO. Sertraline for body dysmorphic disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 1995;34:1404–1405. [PubMed]
  • Emmelkamp PM, Beens H. Cognitive therapy with obsessive-compulsive disorder: a comparative evaluation. Behaviour Research and Therapy. 1991;29:293–300. [PubMed]
  • Emmelkamp PMG, de Lange I. Spouse involvement in the treatment of obsessive-compulsive patients. Behaviour Research and Therapy. 1983;21:341–346. [PubMed]
  • Emmelkamp PMG, Foa EB. Failures are a challenge, Failures in Behaviour Therapy. Foa EB, Emmelkamp PMG, editors. New York: Wiley; 1983. pp. 1–9.
  • Emmelkamp PMG, Giesselbach P. Treatment of obsessions: relevant vs. irrelevant exposure. Behavioural Psychotherapy. 1981;9:322–329.
  • Emmelkamp PMG, Kraanen J. Therapist-controlled exposure in vivo versus self-controlled exposure in vivo: a comparison with obsessive-compulsive patients. Behaviour Research and Therapy. 1977;15:491–495. [PubMed]
  • Emmelkamp PMG, van der Heyden H. Treatment of harming obsessions. Behavioural Analysis and Modification. 1980;4:28–35.
  • Emmelkamp PM, van der Heyden H, van Zanten BL, et al. Treatment of obsessive-compulsive patients: the contribution of self-instructional training to the effectiveness of exposure. Behaviour Research and Therapy. 1980;18:61–66. [PubMed]
  • Emmelkamp PM, Visser S, Hoekstra RJ. Cognitive therapy vs exposure in vivo in the treatment of obsessive-compulsives. Cognitive Therapy and Research. 1988;12:103–114.
  • Emmelkamp PM, van Linden van den Heuvell C, Ruphan M, et al. Home-based treatment of obsessive-compulsive patients: intersession interval and therapist involvement. Behaviour Research and Therapy. 1989;27:89–93. [PubMed]
  • Emmelkamp PMG, de Haan E, Hoogduin CAL. Marital adjustment and obsessive-compulsive disorder. British Journal of Psychiatry. 1990;156:55–60. [PubMed]
  • Enright SJ. Group treatment for obsessive-compulsive disorder: an evaluation. Behavioral Psychotherapy. 1991;19:183–92.
  • Erickson MH. Psychotherapy achieved by a reversal of the neurotic processes in a case of ejaculatio precox. American Journal of Clinical Hypnosis. 1973;15:217–222. [PubMed]
  • Eriksson T. Antiandrogenic treatment for obsessive-compulsive disorder. Am J Psychiatry. 2000 Mar;157(3):483. [PubMed]
  • Erzegovesi S, Ronchi P, Smeraldi E. 5HT-2 receptor and fluvoxamine effect in obsessive-compulsive disorder. Human Psychopharmacology. 1992;7:287–289.
  • Esman AH. Obsessive-compulsive disorder: current views. Psychoanalytic Inquiry. 2001;21:145–156.
  • Fallon BA, Liebowitz MR, Campeas R, et al. Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study. Archives of General Psychiatry. 1998;55:918–924. [PubMed]
  • Fals-Stewart W, Angarano. K. Obsessive-compulsive disorder among patients entering substance abuse treatment: prevalence and accuracy of diagnosis. Journal of Nervous and Mental Disease. 1994;182:715–719. [PubMed]
  • Fals-Stewart W, Marks AP, Schafer J. A comparison of behavioral group therapy and individual behavior therapy in treating obsessive-compulsive disorder. Journal of Nervous and Mental Disease. 1993;181:189–193. [PubMed]
  • Faravelli C, Salvatori S, Galassi F, et al. Epidemiology of somatoform disorders: a community survey in Florence. Social Psychiatry and Psychiatric Epidemiology. 1997;32:24–29. [PubMed]
  • Feldman JD, Noshirvani H, Chu C. Improvement in female patients with severe obsessions and/or compulsions treated with cyproterone acetate. Acta Psychiatrica Scandinavica. 1988;78:254. [PubMed]
  • Fields L. An integrative brief treatment approach for obsessive-compulsive disorder. Journal of Psychotherapy Integration. 1998;8:161–172.
  • Fine S. Family therapy and a behavioral approach to childhood obsessive-compulsive neurosis. Archives of General Psychiatry. 1973;28:695–697. [PubMed]
  • Fineberg NA, Gale TM. Evidence-based pharmacotherapy of obsessive-compulsive disorder. International Journal of Neuropsychopharmacology. 2004;7:1–23. [PubMed]
  • Fineberg NA, Roberts A. Obsessive compulsive disorder: a twenty-first century perspective, Obsessive Compulsive Disorder: A Practical Guide. Fineberg NA, Marazziti D, Stein D, editors. London: Martin Dunitz; 2001. pp. 1–13.
  • Fineberg NA, O’Doherty C, Rajagopal S, et al. How common is obsessive compulsive disorder in a dermatology outpatient clinic? Journal of Clinical Psychiatry. 2003;64:152–155. [PubMed]
  • Finell JS, McDougall J. A case presentation: the treatment of a man with a severe obsessional disorder. Current Issues in Psychoanalytic Practice. 1985;2:3–24.
  • Fingert Chused J. Obsessional manifestations in children. Psychoanalytic Study of the Child. 1999;54:219–232. [PubMed]
  • First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders – Clinician Version (SCID-CV). Washington DC: American Psychiatric Press; 1997.
  • Fischer DJ, Himle JA, Hanna GL. Group behavioral therapy for adolescents with obsessive-compulsive disorder: preliminary outcomes. Research on Social Work Practice. 1998;8:629–636.
  • Flament MF, Rapoport JL, Berg CJ, et al. Clomipramine treatment of childhood obsessive-compulsive disorder: a double-blind controlled study. Archives of General Psychiatry. 1985;42:977–983. [PubMed]
  • Flament MF, Whitaker A, Rapoport JL, et al. Obsessive compulsive disorder in adolescence: an epidemiological study. Journal of the American Academy of Child and Adolescent Psychiatry. 1988;27:764–771. [PubMed]
  • Foa EB, Franklin ME. Psychotherapies for obsessive-compulsive disorder: a review, Obsessive-Compulsive Disorder. Maj M, Sartorius N, Okasha A, et al., editors. New York: John Wiley & Sons Ltd; 2000. pp. 93–146. (WPA series evidence and experience in psychiatry).
  • Foa EB, Goldstein AJ. Continuous exposure and complete response prevention in the treatment of obsessive-compulsive neurosis. Behavior Therapy. 1978;9:821–829.
  • Foa EB, Kozak MJ. Psychological treatment for obsessive-compulsive disorder, Long-Term Treatments of Anxiety Disorders. Mavissakalian MR, Prien RF, editors. Washington, DC: American Psychiatric Association; 1996. pp. 285–309.
  • Foa EB, Steketee G, Milby JB. Differential effects of exposure and response prevention in obsessive-compulsive washers. Journal of Consulting and Clinical Psychology. 1980;48:71–79. [PubMed]
  • Foa EB, Steketee GS, Grayson JB, et al. Deliberate exposure and blocking of obsessive-compulsive rituals: immediate and long-term effects. Behavior Therapy. 1984;15:450–472.
  • Foa EB, Steketee GS, Oazrow BJ. Behavior therapy with obsessive-compulsives: from theory to treatment, Obsessive-Compulsive Disorder: Psychological and Pharmacological Treatments. Mavissakeliam M, Turner SM, Michelson L, editors. New York: Plenum; 1985. pp. 49–120.
  • Foa EB, Kozak MJ, Goodman WK, et al. DSM-IV field trial: obsessive compulsive disorder. Am J Psychiatry. 1995;152(1):90–6. [PubMed]
  • Foa EB, Kozak MJ, Michael J, et al. The validation of a new obsessive-compulsive disorder scale: the obsessive-compulsive inventory. Psychological Assessment. 1998;10:206–214.
  • Foa EB, Franklin ME, Moser J. Context in the clinic: how well do cognitive-behavioral therapies and medications work in combination? Biological Psychiatry. 2002;52:987–997. [PubMed]
  • Foa EB, Huppert JD, Leiberg S, et al. The Obsessive-Compulsive Inventory: development and validation of a short version. Psychological Assessment. 2002;14:485–496. [PubMed]
  • Foa EB, Liebowitz MR, Kozak MJ, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. American Journal of Psychiatry. 2005;162:151–161. [PubMed]
  • Fodstad H, Strandman E, Karlsson B, et al. Treatment of chronic obsessive compulsive states with stereotactic anterior capsulotomy or cingulotomy. Acta Neurochirurgica. 1982;62:1–23. [PubMed]
  • Fontenelle LF, Mendlowicz MV, Marques C, et al. Trans-cultural aspects of obsessive-compulsive disorder: a description of a Brazilian sample and a systematic review of international clinical studies. Journal of Psychiatric Research. 2004;38:403–411. [PubMed]
  • Francis G. Childhood obsessive-compulsive disorder: extinction of compulsive reassurance-seeking. Journal of Anxiety Disorders. 1988;2:361–366.
  • Francobandiera G. Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study. Can J Psychiatry. 2001;46(4):356–358. [PubMed]
  • Franklin ME, Kozak MJ, Cashman LA, et al. Cognitive-behavioral treatment of pediatric obsessive-compulsive disorder: an open clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry. 1998;37:412–419. [PubMed]
  • Franklin ME, Tolin DF, March JS, et al. Treatment of pediatric obsessive-compulsive disorder: a case example of intensive cognitive-behavioral therapy involving exposure and ritual prevention. Cognitive and Behavioral Practice. 2001;8:297–304.
  • Franklin ME, Rynn M, Foa EB, et al. Treatment of obsessive compulsive disorder, Cognitive Therapy With Children and Adolescents: A Casebook for Clinical Practice. Reinecke MA, Datilio FM, Freeman A, editors. New York & London: Guilford Press; 2003. pp. 162–188.
  • Frare P, Lebel A. The use of ‘thought-stopping’ in the treatment of obsessive-compulsive disorder in a 9-year-old girl. Canadian Journal of Psychiatry – Revue Canadienne de Psychiatrie. 1996;41:367–370. [PubMed]
  • Frare F, Perugi G, Ruffolo G, et al. Obsessive-compulsive disorder and body dysmorphic disorder: a comparison of clinical features. European Psychiatry. 2004;19:292–298. [PubMed]
  • Freeling P, Rao BM, Paykel ES, et al. Unrecognised depression in general practice. BMJ (Clinical Research Edition). 1985;290:1880–1883. [PMC free article] [PubMed]
  • Freeman CP, Trimble MR, Deakin JF, et al. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. Journal of Clinical Psychiatry. 1994;55:301–305. [PubMed]
  • Freeman C, Crossley D, Eccleston D. Neurosurgery for Mental Disorder: Report from the Neurosurgery Working Group of the Royal College of Psychiatrists. London: Royal College of Psychiatrists; 2000. p. CR89.
  • Freeston MH. Cognitive-behavioural treatment of a 14-year-old teenager with obsessive-compulsive disorder. Behavioural and Cognitive Psychotherapy. 2001;29:71–84.
  • Freeston M, Rheaume J, Ladouceur R. Correcting faulty appraisals of obsessive thoughts. Behaviour Research and Therapy. 1996;34:446. [PubMed]
  • Freeston MH, Ladouceur R, Gagnon F, et al. Cognitive-behavioral treatment of obsessive thoughts: a controlled study. Journal of Consulting and Clinical Psychology. 1997;65:405–413. [PubMed]
  • Freud S. Notes Upon a Case of Obsessional Neurosis (Reprinted 1955) in The Standard Edition of the Complete Psychological Works of Sigmund Freud. Strachey J, , translator and editor. Vol. 10. London: Hogarth Press; 1909.
  • Friedmann CT, Silvers FM. A multimodality approach to inpatient treatment of obsessive-compulsive disorder. American Journal of Psychotherapy. 1977;31:456–465. [PubMed]
  • Fritzler BK, Hecker JE, Losee MC. Self-directed treatment with minimal therapist contact: preliminary findings for obsessive-compulsive disorder. Behaviour Research and Therapy. 1997;35:627–631. [PubMed]
  • Frost R, Steketee G. Issues in the treatment of compulsive hoarding. Cognitive and Behavioral Practice. 1999;6:397–407.
  • Frost R, Steketee G. Cognitive Approaches to Obsessions and Compulsions: Theory, Assessment, and Treatment. Amsterdam, Netherlands: Pergamon/Elsevier Science Inc.; 2002.
  • Furth GM, Smith R, Kubler-Ross E. Amputee Identity Disorder: Information, Questions, Answers and Recommendations About Self-Demand Amputation. Bloomington: 1st Books Library; 2000.
  • Fux M, Levine J, Aviv A, et al. Inositol treatment of obsessive-compulsive disorder. American Journal of Psychiatry. 1996;153:1219–1221. [PubMed]
  • Fux M, Benjamin J, Belmaker RH. Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study. International Journal of Neuropsychopharmacology. 1999;2:193–195. [PubMed]
  • Gabbard GO. Psychoanalytically informed approaches to the treatment of obsessive-compulsive disorder. Psychoanalytic Inquiry. 2001;21:208–221.
  • Gabriels L, Cosyns P, Nuttin B, et al. Deep brain stimulation for treatment-refractory obsessive-compulsive disorder: psychopathological and neuropsychological outcome in three cases. Acta Psychiatrica Scandinavica. 2003;107:275–282. [PubMed]
  • Garvey MA, Perlmutter SJ, Allen AJ, et al. A pilot study of penicillin prophylaxis for neuropsychiatric exacerbations triggered by streptococcal infections. Biological Psychiatry. 1999;45:1564–1571. [PubMed]
  • Geffken GR, Pincus DB, Zelikovsky N. Obsessive compulsive disorder in children and adolescents: review of background, assessment, and treatment. Journal of Psychological Practice. 1999;5:15–31.
  • Geisler A, Schou M. Lithium for obsessive-compulsive neuroses: a double-blind therapeutic trial. Nordisk Psykiatrisk Tidsskrift. 1969;23:493–495. Danish. [PubMed]
  • Geller D, Biederman J, Jones J, et al. Is juvenile obsessive-compulsive disorder a developmental subtype of the disorder? A review of the pediatric literature. Journal of the American Academy of Child and Adolescent Psychiatry. 1998;37:420–427. [PubMed]
  • Geller DA, Hoog SL, Heiligenstein JH, et al. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry. 2001;40:773–779. [PubMed]
  • Geller DA, Biederman J, Stewart SE, et al. Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials? Journal of Child and Adolescent Psychopharmacology. 2003;13(Suppl 1):S19–S29. [PubMed]
  • Geller DA, Wagner KD, Emslie G, et al. Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry. 2004;43:1387–1396. [PubMed]
  • George MS. New methods of brain stimulation are improving research and therapy in obsessive-compulsive disorder. CNS Spectrum. 2000;5(6 (Suppl 4)):12–17.
  • Geremia GM, Neziroglu F. Cognitive therapy in the treatment of body dysmorphic disorder. Clinical Psychology and Psychotherapy. 2001;8:243–241.
  • Gilbody SM, Whitty PM, Grimshaw JM, et al. Improving the detection and management of depression in primary care. Quality and Safety in Health Care. 2003;12:149–155. [PMC free article] [PubMed]
  • Goktepe EO, Young LB, Bridges PK. A further review of the results of stereotactic subcaudate tractotomy. British Journal of Psychiatry. 1975;126:270–280. [PubMed]
  • Gold-Steinberg S, Logan D. Integrating play therapy in the treatment of children with obsessive-compulsive disorder. American Journal of Orthopsychiatry. 1999;69:495–503. [PubMed]
  • Gomez de Setien DI. Transactional analysis and combined system of therapy for the modification of conduct. Transactional Analysis Journal. 1982;12:267–269.
  • Gomez-Perez JC, Marks IM, Gutierrez-Fisac JL. Dysmorphophobia: clinical features and outcome with behavior therapy. European Psychiatry. 1994;9:229–235.
  • Gomibuchi T, Gomibuchi K, Akiyama T, et al. Obsession of hearing music: from the viewpoint of morita theory. Psychiatry and Clinical Neurosciences. 2000;54:203–206. [PubMed]
  • Goodman R. Psychometric properties of the strengths and difficulties questionnaire. Journal of the American Academy of Child and Adolescent Psychiatry. 2001;40:1337–1345. [PubMed]
  • Goodman RW. Applications of strategic therapy with children. Journal of Child and Adolescent Psychotherapy. 1988;5(1):11–14.

For expert OCD therapy in Newcastle West, Limerick, Cork, Dungarvan, and online, reach out to Claire Russell Therapy today and take control of your mental health!